Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

ODAC Upholds Vote to Revoke Avastin's Breast Cancer Indication

June 29th 2011

An FDA advisory committee unanimously recommended Wednesday that the agency withdraw the breast cancer indication for Avastin.

Dr. Vogelzang Discusses Cabozantinib's Dose Size

June 29th 2011

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Study Reveals Disconnect Between Patient Treatment and Evidence-Based Guidelines

June 27th 2011

Nearly half of older women with advanced breast cancer in the United States failed to receive radiation following a mastectomy.

4 Questions for Martine Piccart-Gebhart, MD, PhD: Noted Breast Cancer Researcher Has Bright Hopes for HER2 Targets

June 27th 2011

Martine Piccart-Gebhart, MD, PhD is a professor of oncology at the Universite Libre de Bruxelles and director of the Medicine department at the Jules Bordet Institute in Brussels, Belgium.

FDA Roundup, Including Latest on Avastin Hearing

June 24th 2011

The FDA recently approved a new drug formulation, mandated label changes for cigarettes and sunscreens, and issued an opinion on breast implants.

HER2 Signaling Beckons: Dimerization Process, Combination Therapies Highlight New Research

June 24th 2011

The first drug that successfully targeted the HER2 pathway in cancer treatment generated much excitement.

Dr. Scher Discusses Circulating Tumor Cells

June 23rd 2011

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells

PER Gatherings Focus on Breast, Lung Cancers

June 23rd 2011

Internationally known experts will discuss the latest research in breast and lung cancers at 2 conferences that the Physicians' Education Resource (PER) is hosting in California in August.

Dr. Vogelzang Describes Cabozantinib's Side Effects

June 21st 2011

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Chemotherapy Improves Survival in Older Women With Advanced ER-Negative Breast Cancer

June 21st 2011

Older women with estrogen receptor (ER)-negative metastatic breast cancer have a 39% lower risk of all-cause mortality if they receive chemotherapy within 6 months of their diagnosis.

Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast Cancer

June 21st 2011

Breast cancers with similar clinicopathologic characteristics may have strikingly different outcomes.

Dr. Vogelzang on Cabozantinib Clinical Trial Results

June 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Adjuvant chemotherapy in breast cancer: An expiration date?

June 20th 2011

One issue that confronts medical oncologists is the explanation of benefits from chemotherapy

New Genetic Test Aids Detection of HER2+ Breast Cancer

June 15th 2011

On Tuesday the FDA approved a genetic test known as Inform Dual ISH that detects HER2+ breast cancer

Disease States: Breast Cancer

June 13th 2011

Breast cancer resources gathered from across the web including a news brief, patient education, clinical trials and CME/CE

Searching for Sharper Images in Breast Screenings

June 13th 2011

Breast imaging technology has evolved in recent years, and although the mammogram remains the gold standard for screening, researchers are excited about the possibilities of molecular breast imaging

Latinas More Likely to Worry About Breast Cancer Recurrence

June 9th 2011

Investigators have documented a wide variation in the extent to which women with early-stage breast cancer worry about the possibility of recurrent disease

Post-Oophorectomy Hormone Replacement Therapy Safe for BRCA1/2 Mutation Carriers

June 7th 2011

Women who present with BRCA1 and BRCA2 mutation face an increased risk of breast and ovarian cancer.

PTEN Expression Does Not Diminish Trastuzumab Effectiveness

June 7th 2011

Phosphatase and tensin homolog (PTEN)-positive breast cancer can be treated with trastuzumab (Herceptin) as effectively as PTEN-negative breast cancer

Deciphering the Challenge of the Genomic Era in Breast Cancer

June 6th 2011

Luminal A genetic signature in node-negative, estrogen receptor- (ER-) positive breast cancer predicts a very high disease-free survival rate